178 related articles for article (PubMed ID: 28449702)
1. Quantification of renal function following stereotactic body radiotherapy for pancreatic cancer: secondary dosimetric analysis of a prospective clinical trial.
Verma V; Bhirud AR; Denniston KA; Bennion NR; Lin C
Radiat Oncol; 2017 Apr; 12(1):71. PubMed ID: 28449702
[TBL] [Abstract][Full Text] [Related]
2. Dosimetric parameters correlate with duodenal histopathologic damage after stereotactic body radiotherapy for pancreatic cancer: Secondary analysis of a prospective clinical trial.
Verma V; Lazenby AJ; Zheng D; Bhirud AR; Ly QP; Are C; Sasson AR; Lin C
Radiother Oncol; 2017 Mar; 122(3):464-469. PubMed ID: 28089484
[TBL] [Abstract][Full Text] [Related]
3. Phase I trial of concurrent stereotactic body radiotherapy and nelfinavir for locally advanced borderline or unresectable pancreatic adenocarcinoma.
Lin C; Verma V; Ly QP; Lazenby A; Sasson A; Schwarz JK; Meza JL; Are C; Li S; Wang S; Hahn SM; Grem JL
Radiother Oncol; 2019 Mar; 132():55-62. PubMed ID: 30825970
[TBL] [Abstract][Full Text] [Related]
4. Phase 2 multi-institutional trial evaluating gemcitabine and stereotactic body radiotherapy for patients with locally advanced unresectable pancreatic adenocarcinoma.
Herman JM; Chang DT; Goodman KA; Dholakia AS; Raman SP; Hacker-Prietz A; Iacobuzio-Donahue CA; Griffith ME; Pawlik TM; Pai JS; O'Reilly E; Fisher GA; Wild AT; Rosati LM; Zheng L; Wolfgang CL; Laheru DA; Columbo LA; Sugar EA; Koong AC
Cancer; 2015 Apr; 121(7):1128-37. PubMed ID: 25538019
[TBL] [Abstract][Full Text] [Related]
5. Pathologic response with neoadjuvant chemotherapy and stereotactic body radiotherapy for borderline resectable and locally-advanced pancreatic cancer.
Rajagopalan MS; Heron DE; Wegner RE; Zeh HJ; Bahary N; Krasinskas AM; Lembersky B; Brand R; Moser AJ; Quinn AE; Burton SA
Radiat Oncol; 2013 Oct; 8():254. PubMed ID: 24175982
[TBL] [Abstract][Full Text] [Related]
6. Comparisons of different neoadjuvant chemotherapy regimens with or without stereotactic body radiation therapy for borderline resectable pancreatic cancer: study protocol of a prospective, randomized phase II trial (BRPCNCC-1).
Gao S; Zhu X; Shi X; Cao K; Bian Y; Jiang H; Wang K; Guo S; Zhang H; Jin G
Radiat Oncol; 2019 Mar; 14(1):52. PubMed ID: 30917842
[TBL] [Abstract][Full Text] [Related]
7. Lymphocyte-Sparing Effect of Stereotactic Body Radiation Therapy in Patients With Unresectable Pancreatic Cancer.
Wild AT; Herman JM; Dholakia AS; Moningi S; Lu Y; Rosati LM; Hacker-Prietz A; Assadi RK; Saeed AM; Pawlik TM; Jaffee EM; Laheru DA; Tran PT; Weiss MJ; Wolfgang CL; Ford E; Grossman SA; Ye X; Ellsworth SG
Int J Radiat Oncol Biol Phys; 2016 Mar; 94(3):571-9. PubMed ID: 26867885
[TBL] [Abstract][Full Text] [Related]
8. AGITG MASTERPLAN: a randomised phase II study of modified FOLFIRINOX alone or in combination with stereotactic body radiotherapy for patients with high-risk and locally advanced pancreatic cancer.
Oar A; Lee M; Le H; Wilson K; Aiken C; Chantrill L; Simes J; Nguyen N; Barbour A; Samra J; Sjoquist KM; Moore A; Espinoza D; Gebski V; Yip S; Chu J; Kneebone A; Goldstein D
BMC Cancer; 2021 Aug; 21(1):936. PubMed ID: 34412605
[TBL] [Abstract][Full Text] [Related]
9. Single-fraction stereotactic body radiation therapy and sequential gemcitabine for the treatment of locally advanced pancreatic cancer.
Schellenberg D; Kim J; Christman-Skieller C; Chun CL; Columbo LA; Ford JM; Fisher GA; Kunz PL; Van Dam J; Quon A; Desser TS; Norton J; Hsu A; Maxim PG; Xing L; Goodman KA; Chang DT; Koong AC
Int J Radiat Oncol Biol Phys; 2011 Sep; 81(1):181-8. PubMed ID: 21549517
[TBL] [Abstract][Full Text] [Related]
10. Gemcitabine chemotherapy and single-fraction stereotactic body radiotherapy for locally advanced pancreatic cancer.
Schellenberg D; Goodman KA; Lee F; Chang S; Kuo T; Ford JM; Fisher GA; Quon A; Desser TS; Norton J; Greco R; Yang GP; Koong AC
Int J Radiat Oncol Biol Phys; 2008 Nov; 72(3):678-86. PubMed ID: 18395362
[TBL] [Abstract][Full Text] [Related]
11. Stereotactic body radiotherapy plus pembrolizumab and trametinib versus stereotactic body radiotherapy plus gemcitabine for locally recurrent pancreatic cancer after surgical resection: an open-label, randomised, controlled, phase 2 trial.
Zhu X; Cao Y; Liu W; Ju X; Zhao X; Jiang L; Ye Y; Jin G; Zhang H
Lancet Oncol; 2022 Mar; 23(3):e105-e115. PubMed ID: 35240087
[TBL] [Abstract][Full Text] [Related]
12. Stereotactic body radiation vs. intensity-modulated radiation for unresectable pancreatic cancer.
Park JJ; Hajj C; Reyngold M; Shi W; Zhang Z; Cuaron JJ; Crane CH; O'Reilly EM; Lowery MA; Yu KH; Goodman KA; Wu AJ
Acta Oncol; 2017 Dec; 56(12):1746-1753. PubMed ID: 28661823
[TBL] [Abstract][Full Text] [Related]
13. Phase I/II Trial of Neoadjuvant Oregovomab-based Chemoimmunotherapy Followed by Stereotactic Body Radiotherapy and Nelfinavir For Locally Advanced Pancreatic Adenocarcinoma.
Lin C; Verma V; Lazenby A; Ly QP; Berim LD; Schwarz JK; Madiyalakan M; Nicodemus CF; Hollingsworth MA; Meza JL; Are C; Padussis J; Grem JL
Am J Clin Oncol; 2019 Oct; 42(10):755-760. PubMed ID: 31513018
[TBL] [Abstract][Full Text] [Related]
14. Stereotactic body radiotherapy and gemcitabine for locally advanced pancreatic cancer.
Mahadevan A; Jain S; Goldstein M; Miksad R; Pleskow D; Sawhney M; Brennan D; Callery M; Vollmer C
Int J Radiat Oncol Biol Phys; 2010 Nov; 78(3):735-42. PubMed ID: 20171803
[TBL] [Abstract][Full Text] [Related]
15. Stereotactic body radiotherapy with or without selective dismutase mimetic in pancreatic adenocarcinoma: an adaptive, randomised, double-blind, placebo-controlled, phase 1b/2 trial.
Taniguchi CM; Frakes JM; Aguilera TA; Palta M; Czito B; Bhutani MS; Colbert LE; Abi Jaoude J; Bernard V; Pant S; Tzeng CD; Kim DW; Malafa M; Costello J; Mathew G; Rebueno N; Koay EJ; Das P; Ludmir EB; Katz MHG; Wolff RA; Beddar S; Sawakuchi GO; Moningi S; Slack Tidwell RS; Yuan Y; Thall PF; Beardsley RA; Holmlund J; Herman JM; Hoffe SE
Lancet Oncol; 2023 Dec; 24(12):1387-1398. PubMed ID: 38039992
[TBL] [Abstract][Full Text] [Related]
16. Baseline metabolic tumor volume and total lesion glycolysis are associated with survival outcomes in patients with locally advanced pancreatic cancer receiving stereotactic body radiation therapy.
Dholakia AS; Chaudhry M; Leal JP; Chang DT; Raman SP; Hacker-Prietz A; Su Z; Pai J; Oteiza KE; Griffith ME; Wahl RL; Tryggestad E; Pawlik T; Laheru DA; Wolfgang CL; Koong AC; Herman JM
Int J Radiat Oncol Biol Phys; 2014 Jul; 89(3):539-46. PubMed ID: 24751410
[TBL] [Abstract][Full Text] [Related]
17. Clinical outcomes and prognostic factors of stereotactic body radiation therapy combined with gemcitabine plus capecitabine for locally advanced unresectable pancreatic cancer.
Shen ZT; Zhou H; Li AM; Ji XQ; Jiang CC; Yuan X; Li B; Zhu XX; Huang GC
J Cancer Res Clin Oncol; 2020 Feb; 146(2):417-428. PubMed ID: 31667573
[TBL] [Abstract][Full Text] [Related]
18. Renal atrophy after stereotactic body radiotherapy for renal cell carcinoma.
Yamamoto T; Kadoya N; Takeda K; Matsushita H; Umezawa R; Sato K; Kubozono M; Ito K; Ishikawa Y; Kozumi M; Takahashi N; Katagiri Y; Onishi H; Jingu K
Radiat Oncol; 2016 May; 11():72. PubMed ID: 27229710
[TBL] [Abstract][Full Text] [Related]
19. SBRT in unresectable advanced pancreatic cancer: preliminary results of a mono-institutional experience.
Tozzi A; Comito T; Alongi F; Navarria P; Iftode C; Mancosu P; Reggiori G; Clerici E; Rimassa L; Zerbi A; Fogliata A; Cozzi L; Tomatis S; Scorsetti M
Radiat Oncol; 2013 Jun; 8():148. PubMed ID: 23799996
[TBL] [Abstract][Full Text] [Related]
20. Unresectable locally advanced pancreatic cancer: a multimodal treatment using neoadjuvant chemoradiotherapy (gemcitabine plus stereotactic radiosurgery) and subsequent surgical exploration.
Polistina F; Costantin G; Casamassima F; Francescon P; Guglielmi R; Panizzoni G; Febbraro A; Ambrosino G
Ann Surg Oncol; 2010 Aug; 17(8):2092-101. PubMed ID: 20224860
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
